View More Recent Stories

Nov 18, 2020 07:00AM Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
Nov 13, 2020 07:00AM Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Nov 11, 2020 07:00AM Milestone Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
Oct 22, 2020 04:24PM Milestone Pharmaceuticals (MIST) Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Oct 22, 2020 04:01PM Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Sep 22, 2020 07:00AM Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
Sep 8, 2020 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 12, 2020 07:00AM Milestone Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Aug 6, 2020 07:00AM Milestone Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Jul 23, 2020 07:15AM Milestone Pharmaceuticals Inc. (MIST) Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
Jul 23, 2020 07:15AM Milestone Pharmaceuticals Inc. (MIST) Announces $25 Million Private Placement of Pre-Funded Warrants
Jul 23, 2020 07:00AM Milestone Pharmaceuticals Announces $25 Million Private Placement
Jul 23, 2020 07:00AM Milestone Pharmaceuticals Announces Regulatory Guidance and Updated Clinical Development Plan for Etripamil in PSVT
May 27, 2020 07:00AM Milestone Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
May 14, 2020 07:15AM Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
Mar 24, 2020 09:14AM Pre-Open Movers 03/24: (GSAT) (NVAX) (CTMX) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
Mar 23, 2020 05:55PM After-Hours Movers 03/23: (GSAT) (VAPO) (PSEC) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
Mar 23, 2020 04:11PM Milestone Pharmaceuticals Inc. (MIST) Reports Topline Results from Phase 3 NODE-301 Trial of Etripamil
Mar 23, 2020 04:05PM Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
Mar 6, 2020 07:00AM Milestone Pharmaceuticals Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Clinical and Corporate Update
View More Recent Stories